SuMMAry
In this case report, the course of arginine vasopressin and copeptin, the stable C-terminal part of the arginine vasopressin precursor, is described during the period of critical illness in a septic shock patient. Arginine vasopressin and copeptin concentrations were substantially increased during the initial 36 hours of shock. Subsequently, both hormones continuously decreased, but exhibited another peak in response to stress during extubation. During restoration of cardiovascular stability, endogenous arginine vasopressin levels further decreased and obviously did not contribute to haemodynamic improvement. In contrast, the decrease in arginine vasopressin and copeptin can be at least partly explained by an improvement of cardiovascular function.
key Words: arginine vasopressin, copeptin, plasma concentrations, sepsis, septic shock Arginine vasopressin (AVP) is one of the most important physiologic shock hormones 1 . AVP is produced in the paraventricular nuclei of the hypothalamus as a pre-pro-hormone. together with AVP and neurophysin II, copeptin, the stable C-terminal part of the AVP precursor, is stored in neurohypophyseal vesicles until secretion upon osmotic and haemodynamic stimuli 1 . once released into the systemic circulation, AVP exerts potent antidiuretic and vasoconstrictive effects 2 . Several studies have indicated that the vasopressinergic system is complexly disturbed in critically ill patients 3 , particularly in those with vasodilatory 4 and septic shock 5, 6 . Although AVP plasma concentrations in patients with septic shock were found to be moderately elevated (3.1±1 pg/ml), it was hypothesized that plasma levels were relatively low for the severity of hypotension 7 . A recent prospective study in septic shock patients reported relative AVP deficiency in approximately one third of patients 8 . A prospective trial in 239 mixed critically ill patients observed significantly increased AVP plasma concentrations 24 hours after admission to the intensive care unit (ICu) when compared with healthy controls (11.9±20.6 vs 0.92±0.38 pg/ml; P<0.001) 3 . Similarly, the same study detected relative AVP deficiency in only a minority of ICu patients (13.4%). Since these studies have so far analysed AVP plasma concentrations only at specific time points or during the initial period of critical illness, nothing is known about the course of AVP plasma concentrations 96 hours after the onset of septic shock.
this case report describes the course of plasma his case report describes the course of plasma AVP concentrations and for comparison the stable C-terminal part of the AVP precursor, copeptin, in a patient with severe septic shock during the entire intensive care unit stay.
CASe hIStory
A 55-year-old male patient with a history of chronic hypertension was admitted to a surgical ICu after laparotomy performed for perforated sigmoid diverticulitis and faecal peritonitis (C-reactive protein, 49.04 mg/dl; cultivation of Streptococcus milleri and E.coli from the peritoneal fluid). on arrival in the ICu, the patient was mechanically ventilated and had septic shock requiring high administration of noradrenaline at the rate of 0.38 µg/kg/min (table 1) . because of oliguric renal failure, continuous veno-venous haemofiltration was started twelve hours after admission (ultrafiltration rate, ~50 litres/24h). Aside from cardiovascular and renal failure, the patient presented with disseminated intravascular coagulation, as well as dysfunction of the lung (P a o 2 / Fio 2 quotient, 234) and the liver (bilirubin 2.34 mg/ dl; ASAt 71 Iu/l; ALAt 49 Iu/l). because of clinical signs of bleeding, one litre of fresh frozen plasma was transfused. Antibiotic therapy was initiated with piperacillin/tazobactam and fluconazole. because of persistent temperatures over 38°C, a new pneumonic infiltrate on the chest X-ray and cultivation of Enterococcus faecium from samples of the upper respiratory tract, antibiotic therapy was changed to vancomycin and imipenem/cilastin on the third day of ICu therapy. thirty-six hours after admission, cardiocirculatory function improved and noradrenaline dosages could be stepwise reduced (table 1) . on day five, noradrenaline infusion as well as continuous veno-venous haemofiltration could be withdrawn. the patient was successfully extubated on ICu day six. After improvement of respiratory and renal function, he was discharged to an intermediate care unit on the surgical department on ICu day twelve. twenty-two days after admission to the ICu, the patient was discharged home.
Immediately after admission to the ICu, plasma concentrations of AVP (radioimmunoassay; Drg radioimmunoassay; Drg Diagnostics, Marburg, germany) and copeptin ) and copeptin (sandwich immunoluminometric assay; b.r.A.h.M.S sandwich immunoluminometric assay; b.r.A.h.M.S Ag, hennigsdorf, germany) were determined.
) were determined. Subsequently, plasma samples were taken every 12 hours during the shock period (admission to day five). During the remaining time on the ICu, plasma AVP and copeptin concentrations were measured in 24 hour intervals. Figure 1 presents the course of plasma AVP and copeptin plasma concentrations.
DISCuSSIon
During the initial period of ICu therapy, plasma AVP concentrations were significantly elevated in this patient with severe septic shock (up to 11.4 pg/ ml; 0.92±0.38 pg/ml in healthy controls) 3 . Similar to the observations of Sharshar and colleagues 8 , AVP concentrations decreased after 36 hours of septic shock in our patient. Although recent publications suggest depletion of neurohypophyseal stores by that time 4, 9 , the decrease in AVP concentrations was also accompanied by a clinically relevant improvement of cardiovascular function (48-120h). through decreased baroreceptor stimulation 1, 2 , this may by itself have contributed to the decrease of AVP concentrations.
When the noradrenaline infusion could be withdrawn (118h), plasma AVP concentrations remained unchanged and even tended to decrease further. this is interesting, because if one assumes AVP deficiency as a cause of excessive vasodilatation in septic shock [4] [5] [6] [7] , it might be speculated that the increase in blood pressure is at least partly attributable to an increase in AVP plasma concentrations (as it is attributable to a decrease in nitric oxide production, up-regulation of adrenergic receptors, and closure of k AtP -channels [10] [11] [12] ). It seems that, at least in our patient, the improvement of cardiovascular function and in particular vascular tone during the recovery period was not caused by an increase of AVP plasma concentrations. Accordingly, in a recent prospective trial, our working group could not detect any relationship between circulatory parameters (e.g. heart rate, mean arterial blood pressure, central venous or pulmonary capillary wedge pressure, cardiac index, vasopressor support) and plasma AVP concentrations 24 hours after admission to the ICu 3 . In addition to AVP, plasma concentrations of copeptin were measured in this patient. because of substantially better ex vivo stability 13 , determination of copeptin levels could be useful to indirectly assess the function of the vasopressinergic system and AVP plasma concentrations. Moreover, particularly for urgent clinical questions in critically ill patients, immunoassays are more widely and rapidly available than radioimmunoassays. In a recent study, septic shock patients had significantly higher copeptin plasma concentrations than healthy volunteers (375 vs 0.88 pmol/l; P<0.0001) 14 . In the presented patient, copeptin concentrations were also increased and exhibited a course similar to AVP plasma concentrations.
In conclusion, AVP and copeptin plasma concentrations were substantially elevated during the initial 36 hours of ICu therapy when the patient was in severe shock. During the subsequent stay in the ICu, AVP and copeptin plasma concentrations continuously decreased but exhibited another peak in response to stress during extubation. During restoration of cardiovascular stability, endogenous AVP levels further decreased and obviously did not contribute to haemodynamic improvement. In contrast, the decrease in AVP and copeptin plasma concentrations can be at least partly explained by an overall improvement of cardiovascular function.
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